Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
Two companies are making life a lot easier for people with diabetes. Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) market devices that allow for convenient monitoring of blood sugar levels ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback